<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02566655</url>
  </required_header>
  <id_info>
    <org_study_id>CSM/OP/2011</org_study_id>
    <secondary_id>2012-005814-20</secondary_id>
    <nct_id>NCT02566655</nct_id>
  </id_info>
  <brief_title>Clinical Trial of Intravenous Infusion of Fucosylated Bone Marrow Mesenchyme Cells in Patients With Osteoporosis</brief_title>
  <acronym>CSM/OP/2011</acronym>
  <official_title>Phase I Clinical Trial To Evaluate The Intravenous Infusion Of Autologous Fucosylated Bone Marrow Mesenchymal Cells Therapy In Patients With Established Osteoporosis and Low Impact Fractures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Red de Terapia Celular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto Murciano de Investigación Biosanitaria Virgen de la Arrixaca</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitario Virgen de la Arrixaca</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Spanish National Health System</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Public Health Service, Murcia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>BIONAND, Universidad de Málaga, IBIMA, Ciber-bbn</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Grupo de Tecnología Sanitaria CIBER-BBN, Inst. Biomecánica de Valencia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Red de Terapia Celular</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety of intravenous infusion of fucosylated&#xD;
      autologous bone marrow cells as a new therapy in patients with established osteoporosis by a&#xD;
      prospective, single-center, open, non-randomized and unblinded clinical trial.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">May 2018</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of serious and non-serious adverse events related to the procedure.</measure>
    <time_frame>24 months from baseline</time_frame>
    <description>During time frame the following items will be considered:&#xD;
Adverse effects related to the infusion moment. Occurrence of infectious complications after infusion of mesenchymal stem cells, because of the immunosuppressive effect of these cells.&#xD;
Appearance of procedure-related neoplasias.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of new fractures</measure>
    <time_frame>24 months from baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain, measured by Visual Analog Scale</measure>
    <time_frame>24 months from baseline</time_frame>
    <description>To measure pain, visual analogue scale (VAS) was used where 0 is no pain and 10 the worst pain imaginable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functionality, measured by Oswestry Disability Questionnaire</measure>
    <time_frame>24 months from baseline</time_frame>
    <description>To identify the functional repercussion of lumbar pain, Oswestry Disability Questionnaire for back pain or Oswestry Disability Index is used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life, measured by EuroQoL-5D test</measure>
    <time_frame>24 months from baseline</time_frame>
    <description>To measure the quality of life EuroQoL-5D psychometric test is used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone resorption, measured by biochemical index</measure>
    <time_frame>24 months from baseline</time_frame>
    <description>Aminoterminal telopeptide of type 1 collagen in the serum (serum NTX) (%) by ELISA technique.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone formation, measured by biochemical index</measure>
    <time_frame>24 months from baseline</time_frame>
    <description>Osteocalcin in the serum by ELISA (BPG serum) (ng / mL) .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone formation, measured by biochemical index</measure>
    <time_frame>24 months from baseline</time_frame>
    <description>Bone specific alkaline phosphatase in the serum by ELISA (serum FAO) (ug / L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone formation, measured by biochemical index</measure>
    <time_frame>24 months from baseline</time_frame>
    <description>Aminoterminal propeptide of procollagen type 1 in the serum by ELISA (serum P1NP) (ng / mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone metabolism, measured by biochemical index</measure>
    <time_frame>24 months from baseline</time_frame>
    <description>Osteoprotegerin (OPG) (pmol / L) in the serum by ELISA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone metabolism, measured by biochemical index</measure>
    <time_frame>24 months from baseline</time_frame>
    <description>Ligand receptor activator of nuclear factor KB (RANKL) (pmol / L) in the serum by ELISA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Mineral Density , measured by dual energy x-ray absorptiometry (DXA)</measure>
    <time_frame>24 months from baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone structure, measured by histomorphometric evaluation</measure>
    <time_frame>baseline and 4 months from baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trabecular bone density measured by quantitative computed tomography of the radius</measure>
    <time_frame>24 months from baseline</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Osteoporosis</condition>
  <condition>Spinal Fractures</condition>
  <arm_group>
    <arm_group_label>Fucosylated MSC for Osteoporosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Autologous Bone Marrow fucosylated mesenchymal stem cells will be infused intravenously on Day 0. The first four patients enrolled will receive a single dose of 2 million cells/Kg and the last six patients enrolled, will receive a single dose of 5 million cells/kg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fucosylated MSC for Osteoporosis</intervention_name>
    <description>Aproximately 30 days before the infusion of the investigational product, patient bone marrow will be obtained according to standard practice of the Haematology University Hospital Virgen de la Arrixaca (HCUVA).&#xD;
Mononuclear bone marrow cells will be separated and cultured in GMP conditions to purify and obtain mesenchymal cell established dose range. The infusion day BM-MSCs will be fucosylated and resuspended in saline to a concentration of 5 million cells per 1 mL. Then, the final product will be packaged in syringes for intravenous administration to patients through a peripheral venous access.</description>
    <arm_group_label>Fucosylated MSC for Osteoporosis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with established osteoporosis according to standard clinical criteria.&#xD;
&#xD;
          -  Patients who give their written informed consent to participate in the study consent.&#xD;
&#xD;
          -  Meet all the inclusion criteria&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with concomitant systemic disease in the opinion of the investigator.&#xD;
&#xD;
          -  Patients with rheumatoid arthritis, ankylosing spondylitis, chronic polyarticular&#xD;
             arthritis.&#xD;
&#xD;
          -  Current patients with neoplasm or history of any malignancy in the last 10 years&#xD;
             except basal carcinoma or epidermoid skin.&#xD;
&#xD;
          -  Patients with genetic disorders that are associated with secondary osteoporosis:&#xD;
             Hemochromatosis, hypophosphatasia, osteogenesis imperfecta, Ehlers-Danlos syndrome,&#xD;
             Marfan syndrome, Riley Day, porphyria, storage diseases syndrome.&#xD;
&#xD;
          -  Patients receiving immunosuppressive chemotherapy or that could interfere with the&#xD;
             process of cell proliferation.&#xD;
&#xD;
          -  Transplant patients: bone marrow, kidney, liver, heart, lung.&#xD;
&#xD;
          -  Patients with clinical criteria and anesthetics that contraindicate well sedation or&#xD;
             bone marrow extraction.&#xD;
&#xD;
          -  Patients participating in a clinical trial in the last 6 months.&#xD;
&#xD;
          -  Patients with positive serology for hepatitis B, hepatitis C or HIV.&#xD;
&#xD;
          -  Patients with inability to understand informed consent.&#xD;
&#xD;
          -  Patients who are pregnant or breast-feeding actively.&#xD;
&#xD;
          -  Patients physically fertile, defined as all women physiologically capable of becoming&#xD;
             pregnant, UNLESS they are using reliable methods of contraception.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luis F Linares Ferrando, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Virgen de la Arrixaca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Clínico Virgen de la Arrixaca</name>
      <address>
        <city>El Palmar</city>
        <state>Murcia</state>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>January 30, 2015</study_first_submitted>
  <study_first_submitted_qc>September 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 2, 2015</study_first_posted>
  <last_update_submitted>October 7, 2020</last_update_submitted>
  <last_update_submitted_qc>October 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Spinal Fractures</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

